An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

Stopped Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.

Conditions

• Fragile X Syndrome
• Behavior
• Cognitive Dysfunction

Interventions

• DRUG: Psilocybin, 1.5 mg

Sponsor

Nova Mentis Life Science Corp

Collaborators

• [object Object]